{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016177", "CSN": null, "TRF": "ORD_1177651_01", "MRN": "46179560", "PhysicianId": "68653", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "883746", "clinicalId": "885151", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1177651_01", "SampleName": "US1139179.01", "Version": "0", "Sample": {"FM_Id": "ORD_1177651_01", "SampleId": "US1139179.01", "BlockId": "S110-16133B", "TRFNumber": "ORD_1177651_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2021_08_31", "processSites": {"processSite": [{"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99552", "MRN": "46179560", "FullName": " \u9673\u598d\u8431", "FirstName": "Yen_Hsuan", "LastName": "Chen", "SubmittedDiagnosis": "Metastatic osteosarcoma, Heart", "Gender": "Female", "DOB": "2007_12_04", "OrderingMD": "\u6d2a\u541b\u5100", "OrderingMDId": "68653", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Heart", "CollDate": "2021_05_10", "ReceivedDate": "2021-09-17 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "5", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ACTB", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ARAF", "isVUS": "true", "variantName": "E578D"}, {"geneName": "BCOR", "isVUS": "true", "variantName": "T366I"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CRLF2", "isVUS": "true", "variantName": "D202N"}, {"geneName": "ERBB3", "isVUS": "true", "variantName": "H1165R"}, {"geneName": "FANCG", "isVUS": "true", "variantName": "A516T"}, {"geneName": "FLCN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "GNA12", "isVUS": "true", "variantName": "amplification"}, {"geneName": "GPR124", "isVUS": "true", "variantName": "C1196Y"}, {"geneName": "KDM2B", "isVUS": "true", "variantName": "G669R"}, {"geneName": "MSH3", "isVUS": "true", "variantName": "P619H"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "STAT4", "isVUS": "true", "variantName": "L307F"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "MYC", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MYC (c_MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). MYC amplification has been reported in 16% of osteosarcoma cases (Smida et al., 2010; 20610556). In osteosarcoma, MYC amplification has been observed frequently with alterations of RB1 (Smida et al., 2010; 20610556). c_MYC expression has been observed in up to 86% (48/56) of osteosarcomas (Wu et al., 2012; 21890444). MYC amplification has been significantly associated with poor prognosis in osteosarcoma (Smida et al., 2010; 20610556). c_MYC expression has also been correlated with a poor prognosis (Wu et al., 2012; 21890444). There are no available therapies that directly target MYC. However, preclinical data indicate that MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41, Mahadeva et al.,2014; 24893165, Park et al., 2019; 31429028), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain_containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). A Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second_line therapy for patients with MYC_overexpressed small cell lung cancer but not for patients without MYC overexpression (Simmons et al., 2020; 31655296). A patient with MYC_amplified invasive ductal breast carcinoma experienced a PR to an Aurora kinase inhibitor (Ganesan et al., 2014; 25253784). The glutaminase inhibitor CB_839, in combination with either everolimus or cabozantinib, has demonstrated encouraging efficacy in Phase 1 and 2 studies enrolling patients with pretreated advanced renal cell carcinoma (Tannir et al., 2018; ASCO GU Abstract 603, Motzer et al., 2019; ESMO Abstract LBA54). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5_fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).", "Include": "true", "ClinicalTrialNote": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03936465", "Include": "true"}, {"nctId": "NCT03220347", "Include": "true"}, {"nctId": "NCT03297424", "Include": "true"}, {"nctId": "NCT01434316", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "C17orf39", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "C17orf39, also known as GID4, encodes a regulatory subunit of the Mediator complex, the human homolog of the yeast Gid E3 ubiquitin ligase complex (Menssen et al, 2012; 22645139). The yeast Gid complex plays a key role in regulation of carbohydrate metabolism (Santt et al., 2008; 18508925). C17orf39 lies in a region of human chromosome 17p11 that is frequently amplified in osteosarcoma (van Dartel et al., 2004; 15193436, Both et al., 2012; 22292074), and observed to be amplified occasionally in other tumor types including gliomas, bladder, esophageal, stomach, prostate and uterine carcinomas (cBioPortal, 2021)(van Dartel et al., 2003; 12645656, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). C17orf39 loss has also been reported, with the highest rates in tumors of the pancreas, prostate, bladder, liver, lung, and ovary (cBioPortal, 2021) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies available to address alterations in C17orf39.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). CDKN2A mutations are found in fewer than 1% osteosarcoma samples in the COSMIC database (Nov 2020)(Tate et al., 2019; 30371878). Chromosomal loss at 9p21, the region that includes CDKN2A, has been reported in 5\u201321% of osteosarcomas examined (Martin et al., 2012; 22685381). CDKN2B mutation was not reported in any of the 175 osteosarcoma cases in COSMIC (Nov 2020)(Tate et al., 2019; 30371878). Loss of CDKN2A expression has been reported to be associated with decreased survival rates in pediatric osteosarcoma patients, and p16INK4a protein levels have been reported to be a sensitive prognostic marker in osteosarcoma (Martin et al., 2012; 22685381, Mohseny et al., 2009; 19718709). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). CDKN2A mutations are found in fewer than 1% osteosarcoma samples in the COSMIC database (Nov 2020)(Tate et al., 2019; 30371878). Chromosomal loss at 9p21, the region that includes CDKN2A, has been reported in 5\u201321% of osteosarcomas examined (Martin et al., 2012; 22685381). CDKN2B mutation was not reported in any of the 175 osteosarcoma cases in COSMIC (Nov 2020)(Tate et al., 2019; 30371878). Loss of CDKN2A expression has been reported to be associated with decreased survival rates in pediatric osteosarcoma patients, and p16INK4a protein levels have been reported to be a sensitive prognostic marker in osteosarcoma (Martin et al., 2012; 22685381, Mohseny et al., 2009; 19718709). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). In osteosarcoma, MSI at any level has been reported in 14% (3/21) to 44% (8/18) of cases with high MSI observed in 11% (2/18) of cases (Heinsohn et al., 2007; 17390023, Belchis et al., 1996; 8866236). However, other studies have reported an absence of MSI in osteosarcoma (0/7 and 0/68) (Suwa et al., 1999; 10370164, Entz_Werl\u00e9 et al., 2005; 15800315) and bone sarcoma (0/29) (Tarkkanen et al., 1996; 8695363). Reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). The prognostic significance of MSI in osteosarcoma or other bone mesenchymal tumors is unknown (PubMed, Sep 2021). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "07", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "07"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Osteosarcoma harbors a median TMB of 2.5 mutations per megabase (muts/Mb), and 0.4% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Undifferentiated pleomorphic sarcomas reportedly have an increased mutation burden compared to Ewing sarcomas or rhabdomyosarcomas (Lim et al., 2015; 26330427, Brohl et al., 2014; 25010205, Chen et al., 2013; 24332040). The association of mutation burden with prognosis of bone sarcoma has not been studied extensively (PubMed, Sep 2021); however, one study of 31 patients with high_grade osteosarcoma reported a significant association of high TMB and improved median OS by multivariate analysis (HR=0.05, p=0.03)(Xie et al., 2021; 33898301). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "MYC", "Alteration": "amplification", "Title": "Study of the Bromodomain (BRD) and Extra_Terminal Domain (BET) Inhibitor BMS_986158 in Pediatric Cancer", "StudyPhase": "PHASE 1", "Target": "BRD2, BRD3, BRD4, BRDT", "Locations": "Toronto (Canada), Michigan, Ohio, Massachusetts, North Carolina", "NCTID": "NCT03936465", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC_90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non_Hodgkin s Lymphomas", "StudyPhase": "PHASE 1", "Target": "BRD2, BRD3, BRD4, BRDT", "Locations": "Kashiwa (Japan), Meldola (Italy), Napoli, Campania (Italy), Rozzano (MI) (Italy), Villejuif (France), Bordeaux (France), Barcelona (Spain), Madrid (Spain)", "NCTID": "NCT03220347", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "A Study of PLX2853 in Advanced Malignancies.", "StudyPhase": "PHASE 1/2", "Target": "BRD4", "Locations": "Arizona, New York, Texas, Virginia, Florida", "NCTID": "NCT03297424", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PARP, CDK1, CDK2, CDK5, CDK9", "Locations": "Massachusetts", "NCTID": "NCT01434316", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "16904903", "FullCitation": "Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903", "Include": "true"}, {"number": "1", "ReferenceId": "10378696", "FullCitation": "Nesbit CE, et al. Oncogene (1999) pmid: 10378696", "Include": "true"}, {"number": "2", "ReferenceId": "15083194", "FullCitation": "Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194", "Include": "true"}, {"number": "3", "ReferenceId": "23574779", "FullCitation": "Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779", "Include": "true"}, {"number": "4", "ReferenceId": "20610556", "FullCitation": "Smida J, et al. Clin. Cancer Res. (2010) pmid: 20610556", "Include": "true"}, {"number": "5", "ReferenceId": "21890444", "FullCitation": "Wu X, et al. Cancer Epidemiol (2012) pmid: 21890444", "Include": "true"}, {"number": "6", "ReferenceId": "22430491", "FullCitation": "Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491", "Include": "true"}, {"number": "7", "ReferenceId": "17589519", "FullCitation": "Goga A, et al. Nat. Med. (2007) pmid: 17589519", "Include": "true"}, {"number": "8", "ReferenceId": "19525400", "FullCitation": "Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400", "Include": "true"}, {"number": "9", "ReferenceId": "31375684", "FullCitation": "Dammert MA, et al. Nat Commun (2019) pmid: 31375684", "Include": "true"}, {"number": "10", "ReferenceId": "28089889", "FullCitation": "Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889", "Include": "true"}, {"number": "11", "ReferenceId": "29088717", "FullCitation": "Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717", "Include": "true"}, {"number": "12", "ReferenceId": "28417568", "FullCitation": "Wang L, et al. Mol Oncol (2017) pmid: 28417568", "Include": "true"}, {"number": "13", "ReferenceId": "25632068", "FullCitation": "Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068", "Include": "true"}, {"number": "14", "ReferenceId": "30226440", "FullCitation": "Li Y, et al. Thyroid (2018) pmid: 30226440", "Include": "true"}, {"number": "15", "ReferenceId": "24893165", "FullCitation": "Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165", "Include": "true"}, {"number": "16", "ReferenceId": "31429028", "FullCitation": "Park SI, et al. Target Oncol (2019) pmid: 31429028", "Include": "true"}, {"number": "17", "ReferenceId": "27496133", "FullCitation": "Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133", "Include": "true"}, {"number": "18", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "19", "ReferenceId": "20643922", "FullCitation": "Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922", "Include": "true"}, {"number": "20", "ReferenceId": "30540594", "FullCitation": "He J, et al. Anticancer Drugs (2019) pmid: 30540594", "Include": "true"}, {"number": "21", "ReferenceId": "25964345", "FullCitation": "Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345", "Include": "true"}, {"number": "22", "ReferenceId": "29156762", "FullCitation": "Effenberger M, et al. Oncotarget (2017) pmid: 29156762", "Include": "true"}, {"number": "23", "ReferenceId": "30103944", "FullCitation": "Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944", "Include": "true"}, {"number": "24", "ReferenceId": "25915584", "FullCitation": "Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584", "Include": "true"}, {"number": "25", "ReferenceId": "21889194", "FullCitation": "Delmore JE, et al. Cell (2011) pmid: 21889194", "Include": "true"}, {"number": "26", "ReferenceId": "24297863", "FullCitation": "Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863", "Include": "true"}, {"number": "27", "ReferenceId": "23582323", "FullCitation": "Lov\u00e9n J, et al. Cell (2013) pmid: 23582323", "Include": "true"}, {"number": "28", "ReferenceId": "31734632", "FullCitation": "Otto C, et al. Neoplasia (2019) pmid: 31734632", "Include": "true"}, {"number": "29", "ReferenceId": "23866964", "FullCitation": "Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964", "Include": "true"}, {"number": "30", "ReferenceId": "26977882", "FullCitation": "Pei Y, et al. Cancer Cell (2016) pmid: 26977882", "Include": "true"}, {"number": "31", "ReferenceId": "30224636", "FullCitation": "Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636", "Include": "true"}, {"number": "32", "ReferenceId": "31655296", "FullCitation": "Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296", "Include": "true"}, {"number": "33", "ReferenceId": "25253784", "FullCitation": "Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784", "Include": "true"}, {"number": "34", "ReferenceId": "23555992", "FullCitation": "Pereira CB, et al. PLoS ONE (2013) pmid: 23555992", "Include": "true"}, {"number": "35", "ReferenceId": "21741827", "FullCitation": "Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827", "Include": "true"}, {"number": "36", "ReferenceId": "11406570", "FullCitation": "Arango D, et al. Cancer Res. (2001) pmid: 11406570", "Include": "true"}, {"number": "37", "ReferenceId": "14516787", "FullCitation": "Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787", "Include": "true"}, {"number": "38", "ReferenceId": "22645139", "FullCitation": "Menssen R, et al. J. Biol. Chem. (2012) pmid: 22645139", "Include": "true"}, {"number": "39", "ReferenceId": "18508925", "FullCitation": "Santt O, et al. Mol. Biol. Cell (2008) pmid: 18508925", "Include": "true"}, {"number": "40", "ReferenceId": "15193436", "FullCitation": "van Dartel M, et al. Cancer Genet. Cytogenet. (2004) pmid: 15193436", "Include": "true"}, {"number": "41", "ReferenceId": "22292074", "FullCitation": "Both J, et al. PLoS ONE (2012) pmid: 22292074", "Include": "true"}, {"number": "42", "ReferenceId": "12645656", "FullCitation": "van Dartel M, et al. Cancer Genet. Cytogenet. (2003) pmid: 12645656", "Include": "true"}, {"number": "43", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "44", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "45", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "46", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "47", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "48", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "49", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "50", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "51", "ReferenceId": "17390023", "FullCitation": "Heinsohn S, et al. Int. J. Oncol. (2007) pmid: 17390023", "Include": "true"}, {"number": "52", "ReferenceId": "8866236", "FullCitation": "Belchis DA, et al. Diagn. Mol. Pathol. (1996) pmid: 8866236", "Include": "true"}, {"number": "53", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "54", "ReferenceId": "15800315", "FullCitation": "Entz_Werl\u00e9 N, et al. J. Clin. Oncol. (2005) pmid: 15800315", "Include": "true"}, {"number": "55", "ReferenceId": "8695363", "FullCitation": "Tarkkanen M, et al. Br. J. Cancer (1996) pmid: 8695363", "Include": "true"}, {"number": "56", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "57", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "58", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "59", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "60", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "61", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "62", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "63", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "64", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "65", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "66", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "67", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "68", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "69", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "70", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "71", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "72", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "73", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "74", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "75", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "76", "ReferenceId": "26330427", "FullCitation": "Lim J, et al. Clin. Cancer Res. (2015) pmid: 26330427", "Include": "true"}, {"number": "77", "ReferenceId": "25010205", "FullCitation": "Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205", "Include": "true"}, {"number": "78", "ReferenceId": "24332040", "FullCitation": "Chen X, et al. Cancer Cell (2013) pmid: 24332040", "Include": "true"}, {"number": "79", "ReferenceId": "33898301", "FullCitation": "Xie L, et al. Front Oncol (2020) pmid: 33898301", "Include": "true"}, {"number": "80", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "81", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "82", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "83", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "84", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "85", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "86", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "87", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "88", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "89", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "90", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "91", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "92", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "93", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "94", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "95", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "96", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "97", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "98", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "99", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "100", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "101", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "102", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "103", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "104", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "105", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "106", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "107", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "108", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "109", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "110", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "111", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "112", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "113", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "114", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "115", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "116", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "117", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "118", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "119", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "120", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "121", "ReferenceId": "22685381", "FullCitation": "Martin JW, et al. Sarcoma (2012) pmid: 22685381", "Include": "true"}, {"number": "122", "ReferenceId": "19718709", "FullCitation": "Mohseny AB, et al. J. Pathol. (2009) pmid: 19718709", "Include": "true"}, {"number": "123", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "124", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "125", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "126", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "127", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "128", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "129", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "130", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "131", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "132", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "133", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "134", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "135", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "136", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "137", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "138", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "139", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "140", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "141", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "142", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "143", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "144", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "145", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_09_15 22:37:02", "OpName": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "811x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "7 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "4 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Soft tissue osteosarcoma (extraskeletal)", "flowcell_analysis": "2000017524", "gender": "female", "pathology_diagnosis": "Osteosarcoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.7.0", "purity_assessment": "95.0", "specimen": "ORD_1177651_01*US1139179.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1177651_01", "test_type": "HemeComplete", "tissue_of_origin": "Heart", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "D2", "mean_exon_depth": "856.76", "name": "SQ_US1139179.01_2", "nucleic_acid_type": "DNA"}, {"bait_set": "R2", "mean_exon_depth": "369.82", "name": "SQ_US1139179.01_1", "nucleic_acid_type": "RNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.488", "cds_effect": "3494A>G", "depth": "789", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "48.8", "position": "chr12:56495137", "protein_effect": "H1165R", "status": "unknown", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.306", "cds_effect": "1856C>A", "depth": "536", "equivocal": "false", "functional_effect": "missense", "gene": "MSH3", "percent_reads": "30.6", "position": "chr5:80057457", "protein_effect": "P619H", "status": "unknown", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.1681", "cds_effect": "2005G>C", "depth": "720", "equivocal": "false", "functional_effect": "missense", "gene": "KDM2B", "percent_reads": "16.81", "position": "chr12:121883176", "protein_effect": "G669R", "status": "unknown", "strand": "_", "transcript": "NM_032590", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.4222", "cds_effect": "1097C>T", "depth": "983", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "42.22", "position": "chrX:39933502", "protein_effect": "T366I", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.2459", "cds_effect": "1546G>A", "depth": "366", "equivocal": "false", "functional_effect": "missense", "gene": "FANCG", "percent_reads": "24.59", "position": "chr9:35075014", "protein_effect": "A516T", "status": "unknown", "strand": "_", "transcript": "NM_004629", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.4446", "cds_effect": "1734G>C", "depth": "542", "equivocal": "false", "functional_effect": "missense", "gene": "ARAF", "percent_reads": "44.46", "position": "chrX:47430769", "protein_effect": "E578D", "status": "unknown", "strand": "+", "transcript": "NM_001654", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.5194", "cds_effect": "604G>A", "depth": "826", "equivocal": "false", "functional_effect": "missense", "gene": "CRLF2", "percent_reads": "51.94", "position": "chrX:1317461", "protein_effect": "D202N", "status": "unknown", "strand": "_", "transcript": "NM_022148", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.5508", "cds_effect": "3587G>A", "depth": "837", "equivocal": "false", "functional_effect": "missense", "gene": "GPR124", "percent_reads": "55.08", "position": "chr8:37699443", "protein_effect": "C1196Y", "status": "unknown", "strand": "+", "transcript": "NM_032777", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"allele_fraction": "0.3679", "cds_effect": "921G>C", "depth": "549", "equivocal": "false", "functional_effect": "missense", "gene": "STAT4", "percent_reads": "36.79", "position": "chr2:191927508", "protein_effect": "L307F", "status": "unknown", "strand": "_", "transcript": "NM_003151", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "9", "equivocal": "false", "gene": "GNA12", "number_of_exons": "4 of 4", "position": "chr7:2770814_2883795", "ratio": "2.36", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "10", "equivocal": "false", "gene": "MYC", "number_of_exons": "5 of 5", "position": "chr8:128706589_128801451", "ratio": "2.87", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "8", "equivocal": "false", "gene": "CARD11", "number_of_exons": "24 of 24", "position": "chr7:2946271_2998201", "ratio": "2.14", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "9", "equivocal": "false", "gene": "SPEN", "number_of_exons": "15 of 15", "position": "chr1:16174539_16265922", "ratio": "2.22", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "14", "equivocal": "false", "gene": "FLCN", "number_of_exons": "12 of 12", "position": "chr17:17116968_17131451", "ratio": "4.5", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "14", "equivocal": "false", "gene": "C17orf39", "number_of_exons": "6 of 6", "position": "chr17:17896081_18015063", "ratio": "4.66", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "10", "equivocal": "false", "gene": "ACTB", "number_of_exons": "5 of 5", "position": "chr7:5567378_5569291", "ratio": "2.58", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21854190_21998002", "ratio": "0.03", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.04", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1139179.01_2"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.52", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}